Abstract 1601P
Background
Little is known about the duration of SARS-CoV-2 antibodies and the factors that influence their durability in oncologic patients. This study aims to study serological response over time by means of a follow-up period of 6, 9 and 12 months. This study also compares patient characteristics by duration of antibody seroprevalence (≥6 months and <6 months) according to treatment groups within the oncological population.
Methods
Observational, unicentric, prospective cohort study. All adult patients with cancer diagnosis within 5 years (2016-April 2020) who accepted participation were included since May 2020. During subsequent months, a comprehensive follow-up of these patients has been performed. Demographic and clinical data was taken from medical records (HCIS, software SAAS) and inputted into a web form (https://forms.epidemixs.org/form/study/covoncoand).
Results
182 oncologic patients with complete data who underwent population serological screening in May 2020 were selected. At baseline, 152 (83.51%) patients had solid tumors and 30 (16.48%) presented with metastatic diseases. Breast cancer was the main primary cancer site with 49 (26.92%) patients. 102 (56.04%) patients received active anti-cancer treatment, of which 48 (47.06%) received chemotherapy, 25 (24.51%) hormonal therapy, 64 (62.74%) biologics and 8 (7.84%) radiotherapy. Of these, 14 patients were seropositive (7.69%). At the 6-month analysis, 156 patients underwent a serological test (1 patient died and 25 did not perform the test) and 10 patients (6.41%) were seropositive. Among the 14 seropositive patients at baseline, only 3 (30.0%) remained positive at 6 months.
Conclusions
Seroprevalence at baseline and at 6 months was lower than observed in the general population in Andorra. Only 3 (30%) patients remained positive at 6 months. No significant differences were observed between overall seroprevalence and anti-cancer treatments. Drawing definitive conclusions is limited by a small sample size.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Servei Andorrà d'Atenció Sanitària.
Funding
Servei Andorrà d'Atenció Sanitària (SAAS).
Disclosure
All authors have declared no conflicts of interest.